Otsuka Holdings Co (4578) AI Stock Analysis

• Market Cap: ¥5.32T
• Dividend Yield: 1.42%
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): 13.0
• Beta (1Y): 0.72
• Revenue Growth: 6.56%
• EPS Growth: 201.49%
• Country: JP
• Employees: 35,338
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 124.25
• Shares Outstanding: 542,988,900
• 10 Day Avg. Volume: 977,130
• 30 Day Avg. Volume: 1,112,043
• PEG Ratio: 1.60
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 1.91
• P/FCF Ratio: 14.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥10,850.00
• Price Target Upside: 33.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 541.86
• Revenue Forecast (FY): ¥2.49T

• Rating: 76 Outperform
• Price Target: ¥12,102.00 ▲(48.49% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by strong financial performance (profitability rebound, high gross margins, and low leverage), partially offset by weaker cash conversion versus EBIT and some historical earnings volatility. Technicals show a strong uptrend but an overbought setup, and valuation is reasonable with a modest dividend.

Positive Factors

Diversified healthcare business model

Otsuka's dual focus on prescription pharmaceuticals and nutraceutical/consumer products creates durable revenue diversification. Prescription drugs provide high-margin, patent-backed sales while consumer health offers stable retail cashflows and channel breadth, reducing single-product cyclicality over time.

High and improving profitability

Very high gross margins and a sustained rebound in net margin indicate structural pricing power and a favorable product mix. These margin levels provide long-term capacity to fund R&D, lifecycle management and shareholder returns, and cushion against cost pressures.

Conservative balance sheet with improving cash generation

Very low leverage preserves financial flexibility while rising free cash flow coverage supports reinvestment and optionality. Strong FCF conversion of earnings enhances capacity for partnerships, milestone-driven investments, and buffers capital allocation through cyclical phases.

Negative Factors

Weak cash conversion versus operating profit

Operating cash flow converting to only ~54% of EBIT signals persistent working-capital or non-cash items that reduce cash available from reported profits. Over time this can limit internal funding for capex, R&D or dividends and raise reliance on balance-sheet flexibility.

Historical earnings volatility and sustainability risk

Prior profit swings and an outsized 2025 growth spike suggest earnings are exposed to episodic factors (product cycles, milestone timing or one-offs). This raises execution risk for consistent margin and revenue expansion and complicates forward planning for investors and management.

Rising absolute debt in 2025

A meaningful jump in total debt, even from low leverage, creates potential future interest and refinancing exposure and reduces the margin of safety if earnings or cash flow weaken. It warrants monitoring of debt use and repayment plans over the medium term.

Otsuka Holdings Co Business Overview & Revenue Model

Company Description

Otsuka Holdings Co., Ltd. is a global healthcare company based in Japan, primarily engaged in the pharmaceutical and nutraceutical sectors. The company operates through two main segments: Pharmaceuticals, which focuses on the development of innovative drugs in areas such as central nervous system disorders, oncology, and cardiovascular health; and Nutraceuticals, which offers products designed to enhance health and wellness, including functional foods and beverages. Otsuka is known for its commitment to research and development, aiming to improve the quality of life through advanced medical solutions and nutritional products.

How the Company Makes Money

Otsuka Holdings generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and treatments for various medical conditions. Key revenue streams come from the commercialization of innovative drugs, particularly in the areas of psychiatry, nephrology, and oncology, as well as from its nutraceutical offerings. The company also engages in strategic partnerships and collaborations with other pharmaceutical companies and research institutions, which can lead to shared development costs and expanded market access. Additionally, Otsuka benefits from licensing agreements and royalties associated with its patented products, further enhancing its earnings potential.

Otsuka Holdings Co Financial Statement Overview

Summary

Strong overall fundamentals: steady multi-year revenue growth with a sharp 2025 acceleration, profitability rebounding to ~14.7% net margin (2024–2025) from ~6.0% (2023), and very conservative leverage (debt-to-equity ~0.10). Offsetting factors are historical profit volatility (2022–2023), a meaningful 2025 debt increase vs. 2024 (despite low leverage), and weaker cash conversion versus EBIT (~54% in 2025).

Income Statement

Revenue has expanded steadily from 2020–2025 (with a sharp acceleration in 2025), while profitability has meaningfully improved versus the 2022–2023 trough: net margin rebounded to ~14.7% in 2024–2025 from ~6.0% in 2023, and operating profitability also stepped up materially. Strengths are high and improving gross profitability (~71.7% in 2025) and strong earnings recovery. Weaknesses include noticeable historical volatility in profits (2022–2023) and an unusually high 2025 revenue growth rate that may prove difficult to sustain.

Balance Sheet

The balance sheet looks conservative, with low leverage (debt-to-equity ~0.10 in 2025) and a large equity base that has grown over time. Returns on equity improved strongly to ~12.0% in 2025 (from ~5.1% in 2023), signaling better capital productivity. Key watch-out: total debt rose meaningfully in 2025 versus 2024, though leverage remains low overall.

Cash Flow

Cash generation is solid and improving: operating cash flow and free cash flow both increased in 2025, and free cash flow rose strongly year over year. Free cash flow covers a large portion of net income (~78% in 2025), supporting earnings quality. Offsetting this, operating cash flow covers only about ~54% of EBIT in 2025 (and has been below ~56% historically), suggesting working-capital or non-cash dynamics that can make cash conversion less consistent than profits.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.47T	2.33T	2.02T	1.74T	1.50T
Gross Profit	1.77T	1.67T	1.41T	1.17T	1.00T
EBITDA	528.60B	452.62B	224.20B	266.93B	244.25B
Net Income	363.15B	343.12B	121.62B	133.91B	125.46B
Balance Sheet
Total Assets	4.20T	3.74T	3.36T	3.10T	2.82T
Cash, Cash Equivalents and Short-Term Investments	534.64B	426.17B	513.34B	471.63B	410.68B
Total Debt	307.04B	189.38B	214.19B	194.16B	212.45B
Total Liabilities	1.10T	961.09B	924.93B	840.17B	775.73B
Stockholders Equity	3.03T	2.73T	2.39T	2.23T	2.01T
Cash Flow
Free Cash Flow	315.74B	225.28B	168.56B	104.06B	115.71B
Operating Cash Flow	403.58B	354.64B	283.23B	211.85B	228.86B
Investing Cash Flow	-161.59B	-268.27B	-190.54B	-81.58B	-95.29B
Financing Cash Flow	-137.34B	-186.89B	-60.17B	-95.47B	-95.84B

Otsuka Holdings Co Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8150.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4578, the sentiment is Neutral. The current price of 8150 is below the 20-day moving average (MA) of 10225.85, below the 50-day MA of 9548.51, and below the 200-day MA of 8212.52, indicating a neutral trend. The MACD of 242.74 indicates Positive momentum. The RSI at 50.98 is Neutral, neither overbought nor oversold. The STOCH value of 21.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4578.

Otsuka Holdings Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4519	84 Outperform	¥16.23T	31.26	20.99%	1.17%	6.25%	2.62%
4578	76 Outperform	¥5.32T	12.95	16.30%	1.42%	6.56%	201.49%
4503	75 Outperform	¥4.32T	9.34	7.97%	3.61%	13.24%	127.88%
4523	68 Neutral	¥1.40T	19.13	5.75%	3.51%	6.79%	22.14%
4502	65 Neutral	¥8.89T	18.42	0.54%	4.11%	-2.84%	-88.29%
4568	63 Neutral	¥5.24T	17.88	16.66%	2.07%	12.56%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Otsuka Holdings Co Corporate Events

Otsuka Holdings to Repurchase and Cancel Up to ¥50 Billion in Shares

Otsuka Holdings has approved a share repurchase program and subsequent cancellation of treasury stock as part of a broader effort to enhance capital efficiency and return profits to shareholders. The board resolution allows the company to buy back up to 7,000,000 common shares, equivalent to about 1.33 percent of shares outstanding excluding treasury stock, for a total outlay of up to ¥50 billion between February 16 and December 23, 2026.

All shares repurchased under this program will be cancelled on January 29, 2027, effectively reducing the company’s share count and potentially boosting per-share metrics for investors. The move underscores a shareholder-friendly capital allocation policy and may strengthen Otsuka’s market positioning by signaling confidence in its financial health and long-term value creation prospects.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen12600.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

Otsuka Weighs Investment Unit Cut to Attract Individual Investors

Otsuka Holdings has outlined its stance on potentially reducing its investment unit, acknowledging that smaller trading units can improve share accessibility for individual investors and help invigorate equity market participation. The company positions this as part of creating a more investable environment for retail shareholders while supporting broader stock market vitality.

Management said it will carefully evaluate any move to lower the investment unit for its shares, weighing market conditions, its share price level, liquidity, and shifts in shareholder structure before deciding on tools such as stock splits. No concrete measures or timelines have been set, signaling a cautious, data-driven approach that leaves current trading conditions unchanged for now but opens the door to future action.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen12600.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

Otsuka Holdings’ Nonconsolidated Profit Falls on Lower Subsidiary Dividends

Otsuka Holdings Co., Ltd. reported a year-on-year decline in its nonconsolidated financial results for the fiscal year ended December 31, 2025, with operating revenues falling 16.3% to ¥98.8 billion and net profit dropping 15.5% to ¥89.9 billion. Earnings per share also decreased from ¥196.52 to ¥169.52, reflecting weaker single-entity performance despite its broader group operations.

The company attributed the downturn primarily to a reduction in dividends received from its subsidiaries, which pressured operating income and ordinary income by nearly 20% compared with the prior year. The results highlight Otsuka Holdings’ dependence on intra-group dividend flows for its standalone profitability, a factor of interest for shareholders assessing the stability of its nonconsolidated earnings base.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen12600.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

Otsuka Holdings Posts Profit Surge in 2025 but Guides to Lower Earnings in 2026

Otsuka Holdings reported fiscal 2025 revenue of ¥2.47 trillion, up 6% year on year, with business profit rising 3.6% to ¥446.1 billion and operating profit jumping 48.2% to ¥479.4 billion. Profit attributable to owners grew 5.8% to ¥363.1 billion, while total assets expanded to ¥4.20 trillion and cash and cash equivalents reached ¥534.6 billion, underscoring a solid financial base.

The company raised its annual dividend to ¥140 per share for 2025 from ¥120 a year earlier and plans to maintain the same level in 2026, signaling continued shareholder returns. For 2026, Otsuka forecasts modest revenue growth of 2.1% but expects double‑digit declines in profit metrics as it absorbs higher costs, even as it expands its consolidation scope with additions such as Araris Biotech AG and Otsuka ICU Medical LLC, which could shape its longer‑term growth profile.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen12600.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

Otsuka’s VOYXACT Gains FDA Approval for IgAN Treatment

Otsuka Holdings has received accelerated FDA approval for VOYXACT, a novel treatment for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This approval, based on significant results from a Phase 3 study, marks a significant advancement in IgAN treatment, offering a new therapeutic option with a unique mechanism of action that targets the APRIL pathway, potentially impacting the company’s market position and providing hope for patients with this chronic kidney disease.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen9950.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.